Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00765518 · ClinicalTrials.gov registry record · Phase 2
Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)
A Phase 2 study, sponsored by Vericel Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00765518 is a Phase 2 study that has completed, run by Vericel Corporation. The registered enrollment target is 40 participants.
The verdict
NCT00765518, a Phase 2 study, has completed, sponsored by Vericel Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study is designed to assess the safety and tolerability of Cardiac Repair Cells (CRCs) compared to standard-of-care in patients with dilated cardiomyopathy (DCM).
Interventions
- OTHER Standard of Care
- BIOLOGICAL Ixmyelocel-T
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-09 |
| Est. Completion | 2012-09-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00765518
The ClinicalTrials.gov registry entry for NCT00765518 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vericel Corporation, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT00765518 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00765518 about?
NCT00765518 is a clinical study titled "Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)". This study is designed to assess the safety and tolerability of Cardiac Repair Cells (CRCs) compared to standard-of-care in patients with dilated cardiomyopathy (DCM).
What is the current status of trial NCT00765518?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2008-09. Estimated completion is 2012-09-05.
What interventions are being tested in trial NCT00765518?
The interventions under investigation include: Standard of Care (OTHER), Ixmyelocel-T (BIOLOGICAL).
Who is sponsoring clinical trial NCT00765518?
This trial is sponsored by Vericel Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.